SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

(ЭN	1B <i>i</i>	APPROVAL

Г

> > 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Footnote⁽⁴⁾

Footnote⁽⁴⁾

Footnote⁽⁴⁾

11. Nature of Indirect Beneficial Ownership (Instr. 4)

																	OIVIE		
to Sec obligat	this box if no le tion 16. Form 4 tions may conti ction 1(b).	or Form 5	STA		l pursu	ant to	Section	n 16(a) of the	Secu	NEFICIA	le Act o		RSF	ΗP	Est		ber: average b esponse:	3235-0287 urden 0.5
	.,				or S	ection	30(h) o	of the	Investm	ent C	ompany Act o	of 1940							
					2. Issuer Name and Ticker or Trading Symbol <u>Oncology Institute</u> , <u>Inc.</u> [TOI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) (First) (Middle) 2100 MCKINNEY AVE, SUITE 1760					3. Date of Earliest Transaction (Month/Day/Year) 09/30/2022								Officer (give title Other (specify below) below)						
					4. lf	Amen	dment,	Date	of Origi	nal Fil	ed (Month/Da	v/Year)		3. Indivi	idual or	Joint/Gro	oup Filii	ng (Chec	k Applicable
(Street) DALLAS TX 75201					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting						
(City)	(St	ate) (2	Zip)												Perso				
		Table	I - No	on-Deriva	ative	Secu	irities	S Ac	quireo	d, Di	sposed of	, or B	enefic	cially	Owne	ed			
1. Title of	Security (Ins	tr. 3)		2. Transacti Date (Month/Day		Exect if any	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)		ed (A) or tr. 3, 4 a	and 5. Amou Securitie Benefici Owned F Reported		s Ily ollowing	Form:	nership Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price	Tr	ransacti nstr. 3 a	on(s)			(Instr. 4)
Common stock 09/30			09/30/20)22			s		11,000	D	\$4.6	8(1)	(1) 14,629,585		I		See Footnote ⁽		
Common stock 10/03/20.)22	22			S		16,765	D	\$4.72	2 ⁽²⁾	(2) 14,612,820		2,820 I		See Footnote ⁽		
Common stock 10/04/20.			22		S		23,447	D	\$4.8	5(3)	5(3) 14,589,373		373		See Footnote ⁽				
		Ta	ble II								oosed of, convertib				wned	I			
1. Title of	2.	3. Transaction		eemed	4.		5. Nu	Imber	6. Dat	e Exe	rcisable and	7. Title	and	8. Pr		9. Numb		10.	11. Natu
Derivative Security (Instr. 3) Conversion Or Exercise Price of Derivative Security		Date (Month/Day/Year)	if any	ıtion Date, h/Day/Year)		action (Instr.			Expiration Date (Month/Day/Year)			Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Secu (Inst	Derivative Security (Instr. 5) Benefic Owned Followim Reporte Transac (Instr. 4)		es Form: ally Direct (D or Indire (I) (Instr. d tion(s)		Benefic Owners oct (Instr. 4
					Code	v	(A)	(D)	Date	isable	Expiration Date	Title	Amount or Number of Shares						
		f Reporting Person [*] Ithcare Partne		<u>.P.</u>															
(Last) 2100 MC	CKINNEY	(First) AVE, SUITE 17	``	liddle)															
(Street) DALLA	S	TX	75	5201															
(City)		(State)	(Z	ip)															
		f Reporting Person [*] Ithcare Partne		<u>P, LLC</u>															
(Last) 2100 MC	CKINNEY	(First) AVE, SUITE 17		1iddle)															
(Street) DALLA	S	ТХ	75	5201															
(City)		(State)	(Z	ïp)															
	nd Address of <u>CI, LLC</u>	f Reporting Person [*]																	

(Last) 2100 MCKINN	(First) EY AVE, SUITE	(Middle)
(Street) DALLAS	ТХ	75201
(City)	(State)	(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.45 to \$4.78, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.47 to \$4.89, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$4.67 to \$5.05, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

4. TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.

Remarks:

<u>/s/ Havencrest Healthcare</u> <u>Partners, L.P., by Kyle Seco,</u> <u>as attorney-in-fact</u>	<u>10/04/2022</u>
/s/ Havencrest Healthcare Partners GP, LLC, by Kyle Seco, as attorney-in-fact	<u>10/04/2022</u>
/s/ TOI HC I, LLC, by Kyle Seco, as attorney-in-fact	10/04/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.